GLP-1 Peptide 10MG

Semaglutide is a long-acting GLP-1 receptor agonist studied for its effects on weight management, glucose regulation, and cardiometabolic health. It is one of the most extensively researched incretin-based peptides with wide clinical use.

BENEFITS

• Weight management — studied for significant and sustained weight loss in clinical trials.
• Glucose regulation — linked to improved HbA1c and insulin sensitivity.
• Cardiometabolic health — interest in lowering cardiovascular risk markers.
• Appetite regulation — GLP-1 activity influences satiety and food intake.
• Widely researched — supported by large clinical programs and published data.

WHAT RESEARCHERS LOOK AT

• GLP-1 receptor activation and downstream insulin/glucagon regulation.
• SUSTAIN clinical trial program in type 2 diabetes and obesity.
• Weight loss and metabolic outcomes compared to other incretin therapies.
• Cardiovascular outcome trials showing risk reduction in high-risk populations.

QUICK SPECS

• Form: Lyophilized peptide
• Net per vial: 10 mg
• Purity: ≥99% (HPLC)
• Identity: MS-verified (per COA)
• Storage: 2–8 °C, protect from light

IDENTITY BASICS

• Type: GLP-1 receptor agonist
• Formula / M.W.: C187H291N45O59, ~4113.6 g/mol
• CAS: 910463-68-2

SELECTED RESEARCH

• PubChem entry — chemical identity:
  
  https://pubchem.ncbi.nlm.nih.gov/compound/56843331
  
• SUSTAIN trials overview:
  
  https://pubmed.ncbi.nlm.nih.gov/28916367/
  
• Weight management outcomes (NEJM, 2021):
  
  https://pubmed.ncbi.nlm.nih.gov/33567185/
  
• Cardiovascular outcomes trial (NEJM, 2016):
  
  https://pubmed.ncbi.nlm.nih.gov/27633186/
  

⚠️ DISCLAIMER

• This product is intended for laboratory research use only.

• Not for human or veterinary use.

• Not approved for diagnostic, therapeutic, or medical applications.

• Handle using appropriate laboratory safety procedures and personal protective equipment.